Berrak zihinler için yalın, zengin, bağımsız bir Türkçe dijital medya üyeliği.
Ücretsiz Kaydol →
Alzheimer’s ile ilgili hikayeler
• Shares in Roche dropped as much as 5.9% on Monday after the Swiss drugmaker announced that its long-awaited drug for Alzheimer’s disease failed in a pair of large studies. The experimental medicine, called gantenerumab, didn’t slow clinical decline in people with early Alzheimer’s at a statistically significant level. via FT The competition: Lecanemab, a similar treatment by Biogen and Eisai, hit a milestone two months ago, becoming the first product to slo...Devamını Oku
15 Kas 2022
• Biogen shares surged more than 35% as the new Alzheimer’s drug it developed with Japan’s Eisai was hailed as an “unequivocal win” by analysts at a late-stage clinical trial, adding more than $10 billion to its market capitalization and putting it on track to erase all of its losses this year. Biogen The trial: Biogen and Eisai said their experimental drug, lecanemab, slowed the progress of the disease by 27% compared with a placebo, in a large trial of pati...Devamını Oku
29 Eyl 2022